Seres Therapeutics Inc (MCRB) reported quarterly earnings results on Thursday, Aug-11-2016. The company reported $-0.70 earnings per share for the quarter, missing the analyst consensus estimate by $-0.25. Analysts had a consensus of $-0.45. The company posted revenue of $3.00 million in the period, compared to analysts expectations of $5.89 million. During the same quarter in the previous year, the company posted $-1.45 EPS.
Many Wall Street Analysts have commented on Seres Therapeutics Inc. Seres Therapeutics Inc was Downgraded by BofA/Merrill to ” Neutral” on Aug 1, 2016. Shares were Reiterated by H.C. Wainwright on Aug 1, 2016 to “Buy” and Lowered the Price Target to $ 15 from a previous price target of $50 .H.C. Wainwright Resumed Seres Therapeutics Inc on Jul 29, 2016 to “Buy”, Price Target of the shares are set at $50.
Seres Therapeutics Inc opened for trading at $9.63 and hit $10.08 on the upside on Monday, eventually ending the session at $9.69, with a gain of 0.94% or 0.09 points. The heightened volatility saw the trading volume jump to 10,42,125 shares. Company has a market cap of $383 M.
In a different news, on Jul 29, 2016, John G. Aunins (Chief Technology Officer & EVP) sold 9,250 shares at $35.00 per share price. According to the SEC, on Jul 29, 2016, Michele Trucksis (Chief Medical Officer and EVP) sold 4,156 shares at $35.18 per share price. On Jul 28, 2016, Roger Pomerantz (President and CEO) sold 20,000 shares at $35.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Seres Therapeutics Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109 which is designed to prevent further recurrences of Clostridium difficile infection (CDI) a debilitating infection of the colon; SER-109; SER-262 and SER-155. It’s SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155 which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.